Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis.

CONTEXT Botulinum toxin A is US Food and Drug Administration approved for prophylactic treatment for chronic migraines. OBJECTIVE To assess botulinum toxin A for the prophylactic treatment of headaches in adults. DATA SOURCES A search of MEDLINE, EMBASE, bibliographies of published systematic reviews, and the Cochrane trial registries between 1966 and March 15, 2012. Inclusion and exclusion criteria of each study were reviewed. Headaches were categorized as episodic (<15 headaches per month) or chronic (≥15 headaches per month) migraine and episodic or chronic daily or tension headaches. STUDY SELECTION Randomized controlled trials comparing botulinum toxin A with placebo or other interventions for headaches among adults. DATA EXTRACTION Data were abstracted and quality assessed independently by 2 reviewers. Outcomes were pooled using a random-effects model. DATA SYNTHESIS Pooled analyses suggested that botulinum toxin A was associated with fewer headaches per month among patients with chronic daily headaches (1115 patients, -2.06 headaches per month; 95% CI, -3.56 to -0.56; 3 studies) and among patients with chronic migraine headaches (n = 1508, -2.30 headaches per month; 95% CI, -3.66 to -0.94; 5 studies). There was no significant association between use of botulinum toxin A and reduction in the number of episodic migraine (n = 1838, 0.05 headaches per month; 95% CI, -0.26 to 0.36; 9 studies) or chronic tension-type headaches (n = 675, -1.43 headaches per month; 95% CI, -3.13 to 0.27; 7 studies). In single trials, botulinum toxin A was not associated with fewer migraine headaches per month vs valproate (standardized mean difference [SMD], -0.20; 95% CI, -0.91 to 0.31), topiramate (SMD, 0.20; 95% CI, -0.36 to 0.76), or amitriptyline (SMD, 0.29; 95% CI, -0.17 to 0.76). Botulinum toxin A was associated with fewer chronic tension-type headaches per month vs methylprednisolone injections (SMD, -2.5; 95% CI, -3.5 to -1.5). Compared with placebo, botulinum toxin A was associated with a greater frequency of blepharoptosis, skin tightness, paresthesias, neck stiffness, muscle weakness, and neck pain. CONCLUSION Botulinum toxin A compared with placebo was associated with a small to modest benefit for chronic daily headaches and chronic migraines but was not associated with fewer episodic migraine or chronic tension-type headaches per month.

[1]  C. Chapple,et al.  The placebo effect in overactive bladder syndrome , 2011, Nature Reviews Urology.

[2]  S. Solomon.  Botulinum Toxin for the Treatment of Chronic Migraine: The Placebo Effect , 2011, Headache.

[3]  Filippo Brighina,et al.  Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study , 2011, The Journal of Headache and Pain.

[4]  F. Chang,et al.  Placebo effect in patients with irritable bowel syndrome , 2011, Journal of gastroenterology and hepatology.

[5]  Richard D Riley,et al.  Interpretation of random effects meta-analyses , 2011, BMJ : British Medical Journal.

[6]  R. Lipton,et al.  Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS) , 2011, Cephalalgia : an international journal of headache.

[7]  N. Poungvarin,et al.  Prophylactic Botulinum Type A Toxin Complex (Dysport®) for Migraine Without Aura , 2011, Headache.

[8]  R. Cady,et al.  A Multi‐Center Double‐Blind Pilot Comparison of OnabotulinumtoxinA and Topiramate for the Prophylactic Treatment of Chronic Migraine , 2011, Headache.

[9]  M. Brin,et al.  placebo-controlled phase of the PREEMPT 2 trial OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, , 2011 .

[10]  H. Injeyan,et al.  An examination of the observed placebo effect associated with the treatment of low back pain - a systematic review. , 2011, Pain research & management.

[11]  Dorothy Becher,et al.  Tricyclic antidepressants and headaches: systematic review and meta-analysis , 2010, BMJ : British Medical Journal.

[12]  W. Becker,et al.  Botulinum Toxin Type A and Acute Drug Costs in Migraine with Triptan Overuse , 2010, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[13]  A. Melo,et al.  Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine , 2010, Clinical Neurology and Neurosurgery.

[14]  H. Diener,et al.  OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial , 2010, Cephalalgia : an international journal of headache.

[15]  W. Becker,et al.  Prophylaxis of migraine headache , 2010, Canadian Medical Association Journal.

[16]  H. Diener,et al.  OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial , 2010, Cephalalgia : an international journal of headache.

[17]  R. Bloomfeld,et al.  An analysis of the placebo effect in Crohn’s disease over time , 2010, Alimentary pharmacology & therapeutics.

[18]  H. Diener,et al.  Guidelines for Controlled Trials of Drugs in Tension-Type Headache: Second Edition , 2010, Cephalalgia : an international journal of headache.

[19]  S. Silberstein,et al.  Migraine prophylaxis with botulinum toxin A is associated with perception of headache. , 2009, Toxicon : official journal of the International Society on Toxinology.

[20]  D. MacGregor,et al.  Botox Treatment for Migraine and Chronic Daily Headache in Adolescents , 2009, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[21]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[22]  A. Straube,et al.  Botulinum Toxin as Preventive Treatment for Migraine: A Randomized Double-Blind Study , 2009, European Neurology.

[23]  R. Harden,et al.  Botulinum Toxin A in the Treatment of Chronic Tension‐Type Headache With Cervical Myofascial Trigger Points: A Randomized, Double‐Blind, Placebo‐Controlled Pilot Study , 2009, Headache.

[24]  H. Neuhauser,et al.  Prevalence and Burden of Headache and Migraine in Germany , 2009, Headache.

[25]  David J Spiegelhalter,et al.  A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.

[26]  S. Hamdy,et al.  Botulinum toxin: could it be an effective treatment for chronic tension-type headache? , 2008, The Journal of Headache and Pain.

[27]  C. Cottrell,et al.  Botulinum Toxin Type‐A (BOTOX®) in the Treatment of Occipital Neuralgia: A Pilot Study , 2008, Headache.

[28]  D. Altman,et al.  Chapter 8: Assessing risk of bias in included studies , 2008 .

[29]  D. Altman,et al.  Assessing Risk of Bias in Included Studies , 2008 .

[30]  R. Cady,et al.  Botulinum Toxin Type A as Migraine Preventive Treatment in Patients Previously Failing Oral Prophylactic Treatment Due To Compliance Issues , 2008, Headache.

[31]  R. Lipton,et al.  Guidelines for Controlled Trials of Prophylactic Treatment of Chronic Migraine in Adults , 2008, Cephalalgia : an international journal of headache.

[32]  A. Straube,et al.  Pericranial injection of botulinum toxin type A (Dysport®) for tension‐type headache – A multicentre, double‐blind, randomized, placebo‐controlled study , 2008, European journal of neurology.

[33]  Jill S. Anderson,et al.  Pain Relief in Patients Receiving Periocular Botulinum Toxin A , 2008, Ophthalmic plastic and reconstructive surgery.

[34]  A. Blumenfeld,et al.  Botulinum Toxin Type A and Divalproex Sodium for Prophylactic Treatment of Episodic or Chronic Migraine , 2007, Headache.

[35]  S. Diamond,et al.  Botulinum Toxin Type A in the Treatment of Chronic Migraine Without Medication Overuse , 2007, Headache.

[36]  N. Mathew,et al.  Predictors of Response to Botulinum Toxin Type A (BoNTA) in Chronic Daily Headache , 2007, Headache.

[37]  A. Dowson,et al.  Clinical Profile of Botulinum Toxin A in Patients with Chronic Headaches and Cervical Dystonia , 2008, Drugs in R&D.

[38]  N. Mekhail,et al.  Botulinum Toxin Occipital Nerve Block for the Treatment of Severe Occipital Neuralgia: A Case Series , 2007, Pain practice : the official journal of World Institute of Pain.

[39]  J. Fuh,et al.  Botulinum Toxin Type A in the Prophylactic Treatment of Transformed Migraine in Taiwanese Patients: A Review of 30 Consecutive Cases , 2007, Journal of the Chinese Medical Association : JCMA.

[40]  Ayhan Varlibaş,et al.  The long-term efficacy and safety of botulinum toxin in refractory chronic tension-type headache , 2007, The Journal of Headache and Pain.

[41]  E. Loder,et al.  A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. , 2007, Pain medicine.

[42]  A. Straube,et al.  Botulinum toxin type-A therapy in cluster headache: an open study , 2007, The Journal of Headache and Pain.

[43]  Botulinum toxin type A in refractory chronic migraine: an open-label trial. , 2007, Arquivos de neuro-psiquiatria.

[44]  J. Schoenen,et al.  A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Multiple Treatments of Botulinum Toxin Type A (BoNTA) for the Prophylaxis of Episodic Migraine Headaches , 2007, Cephalalgia : an international journal of headache.

[45]  William D S Killgore,et al.  Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial. , 2007, Aviation, space, and environmental medicine.

[46]  F. Freitag.  The cycle of migraine: patients' quality of life during and between migraine attacks. , 2007, Clinical therapeutics.

[47]  S. Aurora,et al.  Botulinum Toxin Type A Prophylactic Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Exploratory Study , 2006, Headache.

[48]  F. Sakai,et al.  Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial. , 2007, Internal medicine.

[49]  A. Blumenfeld,et al.  A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. , 2006, The journal of pain : official journal of the American Pain Society.

[50]  R. Jensen,et al.  Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Tension-Type Headache: A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study , 2006, Cephalalgia : an international journal of headache.

[51]  K. Bala,et al.  Botulinum Toxin Type A in Prophylactic Treatment of Migraine , 2006, American journal of therapeutics.

[52]  F. Rico-Villademoros,et al.  Trigger point evaluation in migraine patients: an indication of peripheral sensitization linked to migraine predisposition? , 2006, European journal of neurology.

[53]  A. Sutton,et al.  Comparison of two methods to detect publication bias in meta-analysis. , 2006, JAMA.

[54]  G. Boudreau.  Treatment of Chronic Tension-Type Headache with Botulinum Toxin: a Double-Blind, Placebo-Controlled Clinical Trial , 2005, Cephalalgia : an international journal of headache.

[55]  S. Silberstein,et al.  Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. , 2005, Mayo Clinic proceedings.

[56]  R. Alp,et al.  Botulinum Toxin and Intractable Trigeminal Neuralgia , 2005, Clinical neuropharmacology.

[57]  L. D. Goldberg.  The cost of migraine and its treatment. , 2005, The American journal of managed care.

[58]  C. Turkel,et al.  Botulinum Toxin Type A (BOTOX®) for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 2005, Headache.

[59]  D. Dodick,et al.  Duration of Migraine Is a Predictor for Response to Botulinum Toxin Type A , 2005, Headache.

[60]  S. Evers,et al.  Botulinum Toxin A in the Prophylactic Treatment of Migraine – A Randomized, Double-Blind, Placebo-Controlled Study , 2004, Cephalalgia : an international journal of headache.

[61]  A. Barnard,et al.  Mechanism of Action of Botulinum Toxin Type A in Migraine Prevention: A Pilot Study , 2004, Headache.

[62]  S. Tepper,et al.  Botulinum Neurotoxin Type A in the Preventive Treatment of Refractory Headache: A Review of 100 Consecutive Cases , 2004, Headache.

[63]  J. Pascual.  [Influence of botulinum toxin treatment on previous primary headaches in patients with cranio-cervical dystonia]. , 2004, Neurologia.

[64]  P. Krack,et al.  Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study , 2004, Pain.

[65]  W. Ondo,et al.  Botulinum Toxin a for Chronic Daily Headache: A Randomized, Placebo-Controlled, Parallel Design Study , 2004, Cephalalgia : an international journal of headache.

[66]  B. Guyuron,et al.  Single‐Site Botulinum Toxin Type A Injection for Elimination of Migraine Trigger Points , 2003, Headache.

[67]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[68]  A. Blumenfeld.  Botulinum Toxin Type A as an Effective Prophylactic Treatment in Primary Headache Disorders , 2003, Headache.

[69]  R. Lipton,et al.  The Family Impact of Migraine: Population-Based Studies in the USA and UK , 2003, Cephalalgia : an international journal of headache.

[70]  R. Evans,et al.  Botulinum Toxin Injections for Headache , 2003, Headache.

[71]  Shuu-Jiun Wang.  Epidemiology of migraine and other types of headache in Asia , 2003, Current neurology and neuroscience reports.

[72]  M. Brin,et al.  Botulinum toxin type A (BOTOX) for treatment of migraine. , 2001, Disease-a-month : DM.

[73]  M. Karst,et al.  Botulinum Toxin Type A and EMG: A Key to the Understanding of Chronic Tension‐type Headaches? , 2001, Headache.

[74]  J. Burgunder,et al.  Effect of Botulinum Toxin A Injections in the Treatment of Chronic Tension‐type Headache: A Double‐Blind, Placebo‐Controlled Trial , 2001, Headache.

[75]  G. Zlotnik.  Re: “Botulinum Toxin Type A as a Migraine Preventive Treatment” (Silberstein S, Mathew N, Saper J, Jenkins S, for the BOTOX® Migraine Clinical Research Group. Headache. 2000;40:445‐450) , 2001, Headache.

[76]  M. Brin,et al.  Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study , 2000, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[77]  S. Silberstein,et al.  Botulinum Toxin Type A as a Migraine Preventive Treatment , 2000 .

[78]  R. Dengler,et al.  Treatment of Tension‐type Headache With Botulinum Toxin Type A: A Double‐Blind, Placebo‐Controlled Study , 2000, Headache.

[79]  M. Porta.  Comparative trial of botulinum toxin type A and methylprednisolone for the treatment of tension-type headache , 2000, Current review of pain.

[80]  Stephen J. Sharp,et al.  Meta-analysis regression , 1998 .

[81]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[82]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[83]  R. Lipton,et al.  Classification of Daily and Near‐Daily Headaches: Proposed Revisions to the IHS Criteria , 1994, Headache.

[84]  J. Cutler,et al.  Variance imputation for overviews of clinical trials with continuous response. , 1992, Journal of clinical epidemiology.

[85]  Lewis E. Kazis,et al.  Effect Sizes for Interpreting Changes in Health Status , 1989, Medical care.

[86]  R F Galbraith,et al.  A note on graphical presentation of estimated odds ratios from several clinical trials. , 1988, Statistics in medicine.

[87]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.